Summary:
Click image to enlargeA Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention (See attached ad)
Qualified Participants Must:
• Age of onset of migraines prior to 50 years of age
• Migraine attacks, on average, lasting 4 - 72 hours if untreated
• Per subject report, 4 - 18 migraine attacks of moderate to severe intensity per month within the last 3 months prior to the Screening Visit
• Six or more migraine days during the Observation Period
• Not more than 18 headache days during the Observation Period
• Ability to distinguish migraine attacks from tension/cluster headaches
Qualified Participants May Receive:
Up to $1070 for trial time and participation